ArticleJCO global oncology2021
Article in JCO global oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: A systematic review.Journal of neuroendocrinology · 2025Pooled it
- Efficacy and safety of temozolomide-based regimens in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- Novel framework for response evaluation criteria in grade 1/2 neuroendocrine tumors (RECIN) following [European journal of nuclear medicine and molecular imaging · 2025Trial
- Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia study.European journal of nuclear medicine and molecular imaging · 2026Article
- Global insights into [Scientific reports · 2026Article
- Current Medical Controversies in Zollinger-Ellison Syndrome.Biomedicines · 2025Review
- Recent advances and impending challenges for the radiopharmaceutical sciences in oncology.The Lancet. Oncology · 2024Review
- Efficacy and tolerability of somatostatin analogues according to gender in patients with neuroendocrine tumors.Reviews in endocrine & metabolic disorders · 2024Review
- How to design a theranostic trial?Endocrine oncology (Bristol, England) · 2024Review
- Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.Journal of endocrinological investigation · 2024Review
- Radiotheranostics in oncology: current challenges and emerging opportunities.Nature reviews. Clinical oncology · 2022Review
- Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead.Frontiers in endocrinology · 2022Review
- Chemotherapy in Neuroendocrine Tumors.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the efficacy and safety of MATERIALS AND
methodsData of consecutive patients of advanced inoperable or metastatic grade 1 or 2 GEP-NETs treated with first-line
resultsSeventy-six patients (median age: 53 years; range 14-81 years) with treatment-naïve advanced grade 1 or 2 GEP-NETs were included. Thirty-six patients received a median cumulative dose of 27.3 GBq of
conclusionFirst-line systemic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.